I welcome the Secretary of State’s statement and his ongoing focus on patient safety, which has added so much to the patient experience. I also welcome the fact that he is clearly representing the voice of patients when learning lessons. Many of those who, courageously, have come forward, including many of my own constituents, have been harmed in the private sector. Will he confirm that all patients, wherever they were treated, will be included within the review and that there will be a focus on clinical governance, not only in the NHS but in the private sector?
Medicines and Medical Devices Safety Review
Proceeding contribution from
Sarah Wollaston
(Conservative)
in the House of Commons on Wednesday, 21 February 2018.
It occurred during Ministerial statement on Medicines and Medical Devices Safety Review.
Type
Proceeding contribution
Reference
636 c170 
Session
2017-19
Chamber / Committee
House of Commons chamber
Subjects
Librarians' tools
Timestamp
2020-07-09 15:43:00 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2018-02-21/18022158000251
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2018-02-21/18022158000251
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2018-02-21/18022158000251